Last reviewed · How we verify
Active Clonidine
At a glance
| Generic name | Active Clonidine |
|---|---|
| Also known as | CATAPRES, CATAPRES-TTS, CATAPRES, CATAPRES TTS |
| Sponsor | Hamilton Health Sciences Corporation |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study (PHASE1)
- COMPARISON OF EFFECTS OF GABAPENTIN AND CLONIDINE ON POST-OPERATIVE PAIN AND ANXIETY IN LUMBAR SPINAL SURGERY. (NA)
- Regional Anesthesia EMG Study (NA)
- Clonidine to Prevent Delirium After Electroconvulsive Therapy. (PHASE4)
- A Study to Assess the Effectiveness and Safety of Clonidine Extended-Release OnydaTM XR in Children With ADHD and ODD (PHASE4)
- Mitigating the Pro-inflammatory Phenotype of Obesity (PHASE1)
- ESKETamine for FIBromyalgia Treatment (NA)
- Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Active Clonidine CI brief — competitive landscape report
- Active Clonidine updates RSS · CI watch RSS
- Hamilton Health Sciences Corporation portfolio CI